Curanex Pharmaceuticals Inc. CURX 深 滬
已收盤 05-08 16:00:00 美东时间
0.323
+0.007
+2.34%
華盛通- 最 高0.3397
- 今 開0.32
- 成交量 18.05万股
- 最 低 0.3034
- 昨 收 0.3156
- 總市值 916.18万
- 52周最高 9.1796
- 市盈率 靜 --
- 換手率 0.64%
- 52周最低 0.262
- 委 比 48.15%
- 總股本 2836.48万
- 歷史最高 9.1796
- 量 比 0.86
- 振 幅 11.50%
- 歷史最低 0.262
- 每 手 1
- 風險率 1.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Immutep (NASDAQ:IMMP) shares rose 135.4% to $0.74 during Wednesday's p...
04-15 20:05
EXCLUSIVE: Penny Stock Curanex Expands Cachexia Focus Backed By Patient Recovery Narratives
Curanex highlights patient cases suggesting its lead candidate may aid cachexia and severe disease recovery.
04-08 19:33
EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases
Curanex expands pipeline with cancer cachexia, advances Phyto-N toward IND, and reports preclinical safety data.
04-02 19:53
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
Curanex Pharmaceuticals在制造、毒理学、专利和监管方面取得进展，推动其主要资产Phyto-N溃疡性结肠炎治疗IND申请。公司完成了GLP毒理学研究，扩大知识产权，并评估其他治疗领域。计划于2026年第四季度提交IND，并在澳大利亚启动I期临床，预计溃疡性结肠炎市场到2030年达113.9亿美元。
03-30 21:35
Curanex Phyto-N repeat-dose study shows no toxicology findings at maximum feasible dose
Curanex Phyto-N repeat-dose study shows no toxicology findings at maximum feasible dose Curanex reported results from a 28-day repeat-dose, dose-range finding toxicology study of its botanical drug candidate Phyto-N in Sprague-Dawley rats and dogs. Phyto-N was administered orally twice daily, and no
03-19 08:43
Curanex appoints Taku Kambayashi and Selvakumar Subbian to scientific advisory board
Curanex appoints Taku Kambayashi and Selvakumar Subbian to scientific advisory board Curanex appointed Taku Kambayashi and Selvakumar Subbian to its Scientific Advisory Board. Taku Kambayashi is a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania’s Perelman School of M
03-12 21:30
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers
Curanex Pharmaceuticals Inc. has appointed Dr. Taku Kambayashi and Dr. Selvakumar Subbian to its Scientific Advisory Board, bringing expertise in immunology and infectious diseases to support the company's preclinical studies, IND submission, and clinical trials. Dr. Kambayashi, a professor at the University of Pennsylvania, specializes in immune cell signaling pathways and therapeutic targets for inflammatory diseases. Dr. Subbian, a professor a...
03-12 13:30
Curanex Forms World Class Scientific Advisory Board
<p>Curanex Pharmaceuticals Inc. announced the formation of a new Scientific Advisory Board to support its research, development, clinical trials, and commercialization efforts. The board consists of five world-class members with expertise in life sciences. The company highlighted its lead botanical drug candidate, Phyto-N, which is advancing through FDA-required preclinical studies for potential Phase I clinical trials in late 2026. Phyto-N has s...
03-05 13:00
What's Behind Curanex Pharmaceuticals (CURX) 56% Surge After Hours
Curanex Pharmaceuticals shares surged in after-hours trading after the company completed a GMP-compliant batch supporting its planned IND submission for ulcerative colitis.
02-26 15:11
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers CASI Pharmaceuticals (NASDAQ:CASI) shares rose 54.2% to $0.32 during W...
02-26 05:07
